Q2 sales +50% as iDose TR & Epioxa drive 85% gross margin; 2026 guide raised. Read here for a detailed investment analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results